dprE1 Resolved · high auto-curated

H37Rv Rv3790 · MTBC0 mtbc0_004018 · 461 aa · 4259900–4261285 MTBC0 (+) · RefSeq NP_218307.1

Genomic neighbourhood (genome browser)

Open in full genome browser →

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)decaprenylphosphoryl-beta-D-ribose oxidase
MTBC0 PGAP re-annotationdecaprenylphospho-beta-D-ribofuranose 2-dehydrogenase DprE1
Revised (this work)Decaprenylphospho-beta-D-ribofuranose 2-dehydrogenase DprE1. Pfam: FAD_binding_4 (PF01565.29), ALO (PF04030.20).
Functional category (TubercuList)lipid metabolism

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

In the literature (TB corpus sweep) 241 publications

241 TB publications mention this gene. 241 publications discuss this gene. Queried separately, 238 records carry a M. tuberculosis context and 19 a non-TB mycobacterial context (species named in the 19-record verified sample: M. smegmatis (13), M. abscessus (3), M. leprae (2), M. marinum (1)). The three counts come from three distinct PubMed queries (each with its own context filter), so they neither partition the total nor need to add up to it.

5 of 241: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
In-silico evaluation of Azadirachta indica (neem) against DprE1 of Mycobacterium tuberculosis with functional characterisation. doi:10.1007/s40203-026-00666-9 2026
Molecular docking analysis of DprE1 from M. tuberculosis with phytochemicals. doi:10.6026/973206300221754 2026
Discovery of Potent Benzoselenazinone-Based DprE1 Inhibitors: A Novel Selenium-Containing Scaffold with Superior Anti-TB Activity and Pharmacokinetic Properties. doi:10.1021/acs.jmedchem.5c03770 2026
Thiadiazole-azetidinone sulfonamide hybrids with antimycobacterial activity supported by structure-based analysis. doi:10.1039/d6ra00735j 2026
Exploring the Natural Products Atlas (NPAtlas) Database for Hunting Prospective Irreversible Covalent DprE1 Inhibitors With Antitubercular Activity: An Integrated In-Silico Approach. doi:10.1155/jotm/8879019 2026
254 records returned by the alias sweep (a separate sweep from the 241 above; both are shown, neither is exhaustive)

Searched as: Rv3790, dprE1, Mb3819, ML0109c, MMAR_5352, MSMEG_6382, MAB_0192c — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

PublicationJournalYear
Advances in tuberculosis treatment: novel regimens, new drug pipelines, host-directed therapies, and updated management guidelines. doi:10.1016/j.lanmic.2026.101442 Lancet Microbe 2027
Mechanism of the M. tuberculosis DprE1-DprE2 epimerase complex and inhibition by anti-tubercular drugs. doi:10.1038/s41589-026-02317-8 names it Nat Chem Biol 2026
The Antimycobacterial Activity, Toxicity and Chemical Composition of South African Propolis. doi:10.1002/cbdv.71577 Chem Biodivers 2026
Advancing Therapies for Mycobacterial Diseases: From Small Molecules to Host-Directed Strategies. doi:10.1002/med.70096 Med Res Rev 2026
Exploring the Antitubercular, Antimicrobial Potency, ADME-T Calculations and Docking Studies of 1,2,4-Triazole-Bearing Benzimidazoles. doi:10.1002/cbdv.71539 Chem Biodivers 2026
Design and discovery of 1,4-dihydropyrimidinone-based noncovalent DprE1 inhibitors with integrated biological and computational validation against Mycobacterium tuberculosis. doi:10.1016/j.bioorg.2026.110256 names it Bioorg Chem 2026
In-silico evaluation of Azadirachta indica (neem) against DprE1 of Mycobacterium tuberculosis with functional characterisation. doi:10.1007/s40203-026-00666-9 names it In Silico Pharmacol 2026
Molecular docking analysis of DprE1 from M. tuberculosis with phytochemicals. doi:10.6026/973206300221754 names it Bioinformation 2026
Discovery of Potent Benzoselenazinone-Based DprE1 Inhibitors: A Novel Selenium-Containing Scaffold with Superior Anti-TB Activity and Pharmacokinetic Properties. doi:10.1021/acs.jmedchem.5c03770 names it J Med Chem 2026
Thiadiazole-azetidinone sulfonamide hybrids with antimycobacterial activity supported by structure-based analysis. doi:10.1039/d6ra00735j RSC Adv 2026
Exploring the Natural Products Atlas (NPAtlas) Database for Hunting Prospective Irreversible Covalent DprE1 Inhibitors With Antitubercular Activity: An Integrated In-Silico Approach. doi:10.1155/jotm/8879019 names it J Trop Med 2026
Advancing Tuberculosis Treatment with Next-Generation Drugs and Smart Delivery Systems. doi:10.3390/pharmaceutics18010060 Pharmaceutics 2026
Design, synthesis and biological evaluation of novel quinolinone derivatives as DprE1 inhibitors against Mycobacterium tuberculosis. doi:10.1016/j.bmc.2026.118551 names it Bioorg Med Chem 2026
Nitroquinolones and nitroquinolines: syntheses and antitrypanosomal activity. doi:10.1007/s11030-025-11405-1 Mol Divers 2026
Advancing the antituberculosis activity of nitropicolinic acids and amides. doi:10.1016/j.ejmech.2025.118324 Eur J Med Chem 2026
An integrated computational bioprospection of flavonoids as modulators of Mycobacterium tuberculosis decaprenylphosphoryl-β-d-ribose-2'-epimerase 1. doi:10.1016/j.compbiolchem.2025.108719 Comput Biol Chem 2026
Developing pyrazole-oxadiazole conjugates as potent anti-tubercular agents: an in silico and in vitro approach. doi:10.1039/d5md00902b RSC Med Chem 2025
Discovery, Design, and Synthesis of Novel 2-Benzyl-2,7-diazaspiro[3.5]nonane Benzothiazinones with Broad-Spectrum Antimycobacterial Activity. doi:10.1021/acs.jmedchem.5c02429 J Med Chem 2025
Discovery of potent DprE1-targeted antitubercular agents: synthesis and evaluation of PBTZ169/TBA7371-based derivatives. doi:10.1007/s11030-025-11382-5 names it Mol Divers 2025
Low-level BTZ-043 resistance in Mycobacterium tuberculosis and cross-resistance to bedaquiline and clofazimine. doi:10.5588/ijtldopen.25.0301 IJTLD Open 2025
New drugs for the management of tuberculosis. doi:10.1097/QCO.0000000000001156 Curr Opin Infect Dis 2025
First-in-human study of the benzothiazinone and DprE1 inhibitor BTZ-043, a novel drug candidate for the treatment of Tuberculosis. doi:10.1093/jacamr/dlaf127 names it JAC Antimicrob Resist 2025
Pyrazolopyridine pyrimidone hybrids as potential DprE1 inhibitors, design, synthesis and biological evaluation as antitubercular agents. doi:10.1038/s41598-025-14734-1 names it Sci Rep 2025
A Computational Approach to Repurposing Natural Products for DprE1 Inhibition. doi:10.1155/sci5/2105236 names it Scientifica (Cairo) 2025
A dual-function probe for inhibition and rapid detection of Mycobacterium tuberculosis. doi:10.1039/d5cc02317c Chem Commun (Camb) 2025
In-Silico Exploration of the StreptomeDB Database for Potential Irreversible DprE1 Inhibitors toward Antitubercular Treatment. doi:10.1002/open.202500237 names it ChemistryOpen 2025
Disrupting tuberculosis pathogenesis by targeting DprE1 in cell wall biosynthesis: a structural dynamics perspective. doi:10.1007/s10822-025-00626-z names it J Comput Aided Mol Des 2025
Design, Synthesis, Biological Evaluation, and Computational Studies of Pyrazine-1,3,4-Oxadiazole Analogs as Potential Antitubercular Agents. doi:10.1002/cbdv.202500777 Chem Biodivers 2025
5-(3,5-Dinitrophenyl)-1,3,4-oxadiazol-2-amine derivatives, their precursors, and analogues: Synthesis and evaluation of novel highly potent antitubercular agent. doi:10.1371/journal.pone.0324608 PLoS One 2025
Design, synthesis, biological evaluation, and computational insights of 2-(Aryl)benzo[d]imidazo[2,1-b]thiazole-7-sulfonamide derivatives as potent antitubercular and antibacterial agents. doi:10.1186/s13065-025-01405-5 BMC Chem 2025
Verapamil and its metabolite norverapamil inhibit the Mycobacterium tuberculosis MmpS5L5 efflux pump to increase bedaquiline activity. doi:10.1073/pnas.2426827122 Proc Natl Acad Sci U S A 2025
Bibliometric and Visualization Analysis of DprE1 Inhibitors to Combat Tuberculosis. doi:10.2147/DDDT.S515049 names it Drug Des Devel Ther 2025
DprE1 inhibitors: An insight into the recent developments and synthetic approaches. doi:10.1016/j.ejps.2025.107062 names it Eur J Pharm Sci 2025
Preclinical Evaluation of Selene-Ethylenelacticamides in Tuberculosis: Effects Against Active, Dormant, and Resistant Mycobacterium Tuberculosis and In Vitro Toxicity Investigation. doi:10.3390/microorganisms13020396 Microorganisms 2025
Discovery of novel pyrimidinetrione derivatives as DprE1 inhibitors with potent antimycobacterial activities. doi:10.1016/j.ejmech.2025.117416 names it Eur J Med Chem 2025
Computational approaches: atom-based 3D-QSAR, molecular docking, ADME-Tox, MD simulation and DFT to find novel multi-targeted anti-tubercular agents. doi:10.1186/s13065-024-01357-2 BMC Chem 2025
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043-02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial. doi:10.1016/j.lanmic.2024.07.015 Lancet Microbe 2025
Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis. doi:10.1128/aac.01318-24 Antimicrob Agents Chemother 2025
Noncovalent inhibitors of DprE1 for tuberculosis treatment: design, synthesis, characterization, in vitro and in silico studies of 4-oxo-1,4-dihydroquinazolinylpyrazine-2-carboxamides. doi:10.1080/07391102.2024.2427368 names it J Biomol Struct Dyn 2025
New thiazolyl-isoxazole derivatives as potential anti-infective agents: design, synthesis, in vitro and in silico antimicrobial efficacy. doi:10.1080/07391102.2024.2306497 J Biomol Struct Dyn 2025
3D-QSAR and ADMET studies of morpholino-pyrimidine inhibitors of DprE1 from Mycobacterium tuberculosis. doi:10.1080/07391102.2023.2294496 names it J Biomol Struct Dyn 2025
Benzothiazinone analogs as Anti-Mycobacterium tuberculosis DprE1 irreversible inhibitors: Covalent docking, validation, and molecular dynamics simulations. doi:10.1371/journal.pone.0314422 names it PLoS One 2024
3,5-disubstituted pyridines with potent activity against drug-resistant Mycobacterium tuberculosis clinical isolates. doi:10.1080/17568919.2024.2403963 Future Med Chem 2024
Novel hybrids of 1,2,3-triazole-benzoxazole: design, synthesis, and assessment of DprE1 enzyme inhibitors using fluorometric assay and computational analysis. doi:10.1080/14756366.2024.2403744 names it J Enzyme Inhib Med Chem 2024
Replacement of the essential nitro group by electrophilic warheads towards nitro-free antimycobacterial benzothiazinones. doi:10.1016/j.ejmech.2024.116849 Eur J Med Chem 2024
Design, synthesis and antimycobacterial activity of novel benzothiazinones with improved water solubility. doi:10.1016/j.ejmech.2024.116829 Eur J Med Chem 2024
The Mycobacterium tuberculosis Cell Wall: An Alluring Drug Target for Developing Newer Anti-TB Drugs-A Perspective. doi:10.1111/cbdd.14612 Chem Biol Drug Des 2024
Pharmacophore mapping, 3D QSAR, molecular docking, and ADME prediction studies of novel Benzothiazinone derivatives. doi:10.1007/s40203-024-00255-8 In Silico Pharmacol 2024
Development and Evaluation of Bis-benzothiazoles as a New Class of Benzothiazoles Targeting DprE1 as Antitubercular Agents. doi:10.1021/acsinfecdis.4c00415 names it ACS Infect Dis 2024
Efficacy of macozinone in mice with genetically diverse susceptibility to Mycobacterium tuberculosis infection. doi:10.1016/j.micinf.2024.105376 Microbes Infect 2024
DprE1 and Ddn as promising therapeutic targets in the development of novel anti-tuberculosis nitroaromatic drugs. doi:10.1016/j.ejmech.2024.116559 names it Eur J Med Chem 2024
Targeting decaprenylphosphoryl-β-D-ribose 2'-epimerase for Innovative Drug Development Against Mycobacterium Tuberculosis Drug-Resistant Strains. doi:10.1177/11779322241257039 Bioinform Biol Insights 2024
Synthesis, Activity, Toxicity, and In Silico Studies of New Antimycobacterial N-Alkyl Nitrobenzamides. doi:10.3390/ph17050608 Pharmaceuticals (Basel) 2024
Development of New Drugs to Treat Tuberculosis Based on the Dinitrobenzamide Scaffold. doi:10.3390/ph17050559 Pharmaceuticals (Basel) 2024
Identification of DprE1 inhibitors for tuberculosis through integrated in-silico approaches. doi:10.1038/s41598-024-61901-x names it Sci Rep 2024
Recent advances in the development of DprE1 inhibitors using AI/CADD approaches. doi:10.1016/j.drudis.2024.103987 names it Drug Discov Today 2024
Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3-Triazoles: A Computational Docking Techniques. doi:10.1002/cbdv.202400389 Chem Biodivers 2024
Structure-based drug design and characterization of novel pyrazine hydrazinylidene derivatives with a benzenesulfonate scaffold as noncovalent inhibitors of DprE1 tor tuberculosis treatment. doi:10.1007/s11030-024-10812-0 names it Mol Divers 2024
Bactericidal and sterilizing activity of novel regimens combining bedaquiline or TBAJ-587 with GSK2556286 and TBA-7371 in a mouse model of tuberculosis. doi:10.1128/aac.01562-23 Antimicrob Agents Chemother 2024
N-Substituted piperazine-coupled imidazo[2,1-b]thiazoles as inhibitors of Mycobacterium tuberculosis: Synthesis, evaluation, and docking studies. doi:10.1002/ddr.22153 Drug Dev Res 2024
Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy. doi:10.1186/s13063-024-07912-5 Trials 2024
Discovery of N-(1-(6-Oxo-1,6-dihydropyrimidine)-pyrazole) Acetamide Derivatives as Novel Noncovalent DprE1 Inhibitors against Mycobacterium tuberculosis. doi:10.1021/acs.jmedchem.3c01703 names it J Med Chem 2024
Both Nitro Groups Are Essential for High Antitubercular Activity of 3,5-Dinitrobenzylsulfanyl Tetrazoles and 1,3,4-Oxadiazoles through the Deazaflavin-Dependent Nitroreductase Activation Pathway. doi:10.1021/acs.jmedchem.3c00925 J Med Chem 2024
Novel indolinone-tethered benzothiophenes as anti-tubercular agents against MDR/XDR M. tuberculosis: Design, synthesis, biological evaluation and in vivo pharmacokinetic study. doi:10.1016/j.bioorg.2023.107009 Bioorg Chem 2024
Benzothiozinone derivatives with anti-tubercular Activity-Further side chain investigation. doi:10.1016/j.ejmech.2023.115976 Eur J Med Chem 2024
Design, synthesis and antitubercular assessment of 1, 2, 3-triazole incorporated thiazolylcarboxylate derivatives. doi:10.1016/j.bmcl.2023.129551 Bioorg Med Chem Lett 2024
A Rational Approach To Antitubercular Drug Design: Molecular Docking, Prediction of ADME Properties and Evaluation of Antitubercular Activity of Novel Isonicotinamide Scaffold. doi:10.2174/2772434418666230710142852 Recent Adv Antiinfect Drug Discov 2024
Design, synthesis, biological evaluation and molecular dynamics of some novel 3-phenylpyrazolo[1,5-a]pyrimidine-2,7(1H,4H)-dione based compounds as anti-tubercular agents. doi:10.1080/07391102.2023.2249109 J Biomol Struct Dyn 2024
Structure-activity relationship mediated molecular insights of DprE1 inhibitors: A Comprehensive Review. doi:10.1080/07391102.2023.2230312 names it J Biomol Struct Dyn 2024
Identification of novel inhibitors for trigger factor (TF) of M. tb: an in silico investigation. doi:10.1080/07391102.2023.2218937 J Biomol Struct Dyn 2024
Novel Antitubercular Agents: Design, Synthesis, Molecular Dynamic and Biological Studies of Pyrazole - 1,2,4-Triazole Conjugates. doi:10.1002/cbdv.202300971 Chem Biodivers 2023
Drug distribution and efficacy of the DprE1 inhibitor BTZ-043 in the C3HeB/FeJ mouse tuberculosis model. doi:10.1128/aac.00597-23 names it Antimicrob Agents Chemother 2023
Selection of Multi-Drug Targets against Drug-Resistant Mycobacterium tuberculosis XDR1219 Using the Hyperbolic Mapping of the Protein Interaction Network. doi:10.3390/ijms241814050 Int J Mol Sci 2023
Synthesis and Structure-Activity Relationships of a New Class of Oxadiazoles Targeting DprE1 as Antitubercular Agents. doi:10.1021/acsmedchemlett.3c00295 names it ACS Med Chem Lett 2023
Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis. doi:10.1128/spectrum.04721-22 names it Microbiol Spectr 2023
Design and synthesis of benzofuran- and naphthalene-fused thiazinones as antimycobacterial agents. doi:10.1002/ardp.202300356 Arch Pharm (Weinheim) 2023
Discovery of pyrimidine-tethered benzothiazole derivatives as novel anti-tubercular agents towards multi- and extensively drug resistant Mycobacterium tuberculosis. doi:10.1080/14756366.2023.2250575 J Enzyme Inhib Med Chem 2023
Discovery and characterization of antimycobacterial nitro-containing compounds with distinct mechanisms of action and in vivo efficacy. doi:10.1128/aac.00474-23 Antimicrob Agents Chemother 2023
Side Chain-Modified Benzothiazinone Derivatives with Anti-Mycobacterial Activity. doi:10.3390/biomedicines11071975 Biomedicines 2023
Recent advances in the synthesis of new benzothiazole based anti-tubercular compounds. doi:10.1039/d3ra03862a RSC Adv 2023
2,6-Disubstituted 7-(naphthalen-2-ylmethyl)-7H-purines as a new class of potent antitubercular agents inhibiting DprE1. doi:10.1016/j.ejmech.2023.115611 names it Eur J Med Chem 2023
Quinolone analogues of benzothiazinone: Synthesis, antitubercular structure-activity relationship and ADME profiling. doi:10.1016/j.ejmech.2023.115539 Eur J Med Chem 2023
DprE1 Inhibitors: Enduring Aspirations for Future Antituberculosis Drug Discovery. doi:10.1002/cmdc.202300099 names it ChemMedChem 2023
Mycobacterium tuberculosis Adaptation in Response to Isoniazid Treatment in a Multi-Stress System That Mimics the Host Environment. doi:10.3390/antibiotics12050852 Antibiotics (Basel) 2023
Pharmacokinetics and Efficacy of the Benzothiazinone BTZ-043 against Tuberculous Mycobacteria inside Granulomas in the Guinea Pig Model. doi:10.1128/aac.01438-22 Antimicrob Agents Chemother 2023
Exploring biogenic chalcones as DprE1 inhibitors for antitubercular activity via in silico approach. doi:10.1007/s00894-023-05521-8 names it J Mol Model 2023
Identification of a Chemical Inhibitor with a Novel Scaffold Targeting Decaprenylphosphoryl-β-D-Ribose Oxidase (DprE1). doi:10.2174/1871526523666230309110705 names it Infect Disord Drug Targets 2023
Computer-assisted discovery of safe and effective DprE1/ aaRSs Inhibitors against TB utilizing Drug Repurposing approach. doi:10.1016/j.jiph.2023.02.005 names it J Infect Public Health 2023
Dihydroisocoumarins and Phenylglycosides from Scorzonera longiana, Their Antimicrobial Activities and Molecular Docking Studies. doi:10.1002/cbdv.202201052 Chem Biodivers 2023
Targeting mycobacterial membranes and membrane proteins: Progress and limitations. doi:10.1016/j.bmc.2023.117212 Bioorg Med Chem 2023
Mutations in Rv0678 Reduce Susceptibility of Mycobacterium tuberculosis to the DprE1 Inhibitor TBA-7371. doi:10.1128/aac.00052-23 names it Antimicrob Agents Chemother 2023
Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis. doi:10.1099/mic.0.001288 Microbiology (Reading) 2023
Synthesis, antitubercular evaluation, and molecular docking studies of hybrid pyridinium salts derived from isoniazid. doi:10.1002/ddr.22039 Drug Dev Res 2023
Solubility-driven optimization of benzothiopyranone salts leading to a preclinical candidate with improved pharmacokinetic properties and activity against Mycobacterium tuberculosis. doi:10.1016/j.ejmech.2022.114993 Eur J Med Chem 2023
Design, synthesis, and computational studies of benzimidazole derivatives as new antitubercular agents. doi:10.1080/07391102.2022.2036241 J Biomol Struct Dyn 2023
QSAR Studies, Molecular Docking, Molecular Dynamics, Synthesis, and Biological Evaluation of Novel Quinolinone-Based Thiosemicarbazones against Mycobacterium tuberculosis. doi:10.3390/antibiotics12010061 Antibiotics (Basel) 2022
Ethionamide and Prothionamide Based Coumarinyl-Thiazole Derivatives: Synthesis, Antitubercular Activity, Toxicity Investigations and Molecular Docking Studies. doi:10.1007/s11094-022-02782-0 Pharm Chem J 2022
Novel 1,2,3-Triazole-Based Benzothiazole Derivatives: Efficient Synthesis, DFT, Molecular Docking, and ADMET Studies. doi:10.3390/molecules27238555 Molecules 2022
Insights into development of Decaprenyl-phosphoryl-β-D-ribose 2'-epimerase (DprE1) inhibitors as antitubercular agents: A state of the art review. doi:10.1016/j.ijtb.2021.09.003 names it Indian J Tuberc 2022
Recent Advances of DprE1 Inhibitors against Mycobacterium tuberculosis: Computational Analysis of Physicochemical and ADMET Properties. doi:10.1021/acsomega.2c05307 names it ACS Omega 2022
Mycobacterium tuberculosis DprE1 Inhibitor OPC-167832 Is Active against Mycobacterium abscessus In Vitro. doi:10.1128/aac.01237-22 names it Antimicrob Agents Chemother 2022
Identification of hydantoin based Decaprenylphosphoryl-β-D-Ribose Oxidase (DprE1) inhibitors as antimycobacterial agents using computational tools. doi:10.1038/s41598-022-20325-1 names it Sci Rep 2022
An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis. doi:10.1016/j.jiph.2022.08.016 names it J Infect Public Health 2022
Indole: A promising scaffold for the discovery and development of potential anti-tubercular agents. doi:10.1016/j.crphar.2022.100119 Curr Res Pharmacol Drug Discov 2022
BTZ-Derived Benzisothiazolinones with In Vitro Activity against Mycobacterium tuberculosis. doi:10.1021/acsmedchemlett.2c00215 ACS Med Chem Lett 2022
Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis. doi:10.1128/aac.00904-22 names it Antimicrob Agents Chemother 2022
Bioevaluation of quinoline-4-carbonyl derivatives of piperazinyl-benzothiazinones as promising antimycobacterial agents. doi:10.1002/ardp.202200168 Arch Pharm (Weinheim) 2022
Synthesis and evaluation of triazole congeners of nitro-benzothiazinones potentially active against drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy. doi:10.1039/d1md00387a RSC Med Chem 2022
Identification of Mutations Associated With Macozinone-Resistant in Mycobacterium Tuberculosis. doi:10.1007/s00284-022-02881-x Curr Microbiol 2022
Development of 6-Methanesulfonyl-8-nitrobenzothiazinone Based Antitubercular Agents. doi:10.1021/acsmedchemlett.1c00652 ACS Med Chem Lett 2022
Synthesis of Novel Derivatives of 5,6,7,8-Tetrahydroquinazolines Using α-Aminoamidines and In Silico Screening of Their Biological Activity. doi:10.3390/ijms23073781 Int J Mol Sci 2022
Functional investigation of the antitubercular drug target Decaprenylphosphoryl-β-D-ribofuranose-2-epimerase DprE1/DprE2 complex. doi:10.1016/j.bbrc.2022.03.091 names it Biochem Biophys Res Commun 2022
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. doi:10.1128/aac.02398-21 Antimicrob Agents Chemother 2022
Mandelic acid-based spirothiazolidinones targeting M. tuberculosis: Synthesis, in vitro and in silico investigations. doi:10.1016/j.bioorg.2022.105688 Bioorg Chem 2022
New Insight into Dearomatization and Decarbonylation of Antitubercular 4H-Benzo[e][1,3]thiazinones: Stable 5H- and 7H-Benzo[e][1,3]thiazines. doi:10.1002/cmdc.202200021 ChemMedChem 2022
The Regulation of ManLAM-Related Gene Expression in Mycobacterium tuberculosis with Different Drug Resistance Profiles Following Isoniazid Treatment. doi:10.2147/IDR.S346869 Infect Drug Resist 2022
Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis. doi:10.1016/j.ejmech.2022.114145 Eur J Med Chem 2022
The Veterinary Anti-Parasitic Selamectin Is a Novel Inhibitor of the Mycobacterium tuberculosis DprE1 Enzyme. doi:10.3390/ijms23020771 names it Int J Mol Sci 2022
Efficient Synthesis of Benzothiazinone Analogues with Activity against Intracellular Mycobacterium tuberculosis. doi:10.1002/cmdc.202100733 ChemMedChem 2022
Development of potent nanosized isatin-isonicotinohydrazide hybrid for management of Mycobacterium tuberculosis. doi:10.1016/j.ijpharm.2021.121369 Int J Pharm 2022
Exploring disordered loops in DprE1 provides a functional site to combat drug-resistance in Mycobacterium strains. doi:10.1016/j.ejmech.2021.113932 names it Eur J Med Chem 2022
Discovery of novel DprE1 inhibitors via computational bioactivity fingerprints and structure-based virtual screening. doi:10.1038/s41401-021-00779-1 names it Acta Pharmacol Sin 2022
Structural and Activity Relationships of 6-Sulfonyl-8-Nitrobenzothiazinones as Antitubercular Agents. doi:10.1021/acs.jmedchem.1c01049 J Med Chem 2021
1,3-Diarylpyrazolyl-acylsulfonamides as Potent Anti-tuberculosis Agents Targeting Cell Wall Biosynthesis in Mycobacterium tuberculosis. doi:10.1021/acs.jmedchem.1c00837 J Med Chem 2021
Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 Inhibitors TBA-7371, PBTZ169, and OPC-167832. doi:10.1128/AAC.00583-21 names it Antimicrob Agents Chemother 2021
Synthesis, structural characterization and antimycobacterial evaluation of several halogenated non-nitro benzothiazinones. doi:10.1007/s00044-021-02735-4 Med Chem Res 2021
Chemical Space Exploration of DprE1 Inhibitors Using Chemoinformatics and Artificial Intelligence. doi:10.1021/acsomega.1c01314 names it ACS Omega 2021
Hydride-induced Meisenheimer complex formation reflects activity of nitro aromatic anti-tuberculosis compounds. doi:10.1039/d0md00390e RSC Med Chem 2021
Synthesis of alkynylated 1,2,4-oxadiazole/1,2,3-1H-triazole glycoconjugates: Discovering new compounds for use in chemotherapy against lung carcinoma and Mycobacterium tuberculosis. doi:10.1016/j.ejmech.2021.113472 Eur J Med Chem 2021
Discovery of Novel Thiophene-arylamide Derivatives as DprE1 Inhibitors with Potent Antimycobacterial Activities. doi:10.1021/acs.jmedchem.1c00263 names it J Med Chem 2021
In silico guided design of non-covalent inhibitors of DprE1: synthesis and biological evaluation. doi:10.1080/1062936X.2021.1900390 names it SAR QSAR Environ Res 2021
Synthetic molecules as DprE1 inhibitors: A patent review. doi:10.1080/13543776.2021.1902990 names it Expert Opin Ther Pat 2021
Easily accessed nitroquinolones exhibiting potent and selective anti-tubercular activity. doi:10.1016/j.ejmech.2021.113207 Eur J Med Chem 2021
Molecular Docking Suggests the Targets of Anti-Mycobacterial Natural Products. doi:10.3390/molecules26020475 Molecules 2021
Development of novel isatin-nicotinohydrazide hybrids with potent activity against susceptible/resistant Mycobacterium tuberculosis and bronchitis causing-bacteria. doi:10.1080/14756366.2020.1868450 J Enzyme Inhib Med Chem 2021
Virtual screening and free energy estimation for identifying Mycobacterium tuberculosis flavoenzyme DprE1 inhibitors. doi:10.1016/j.jmgm.2020.107770 names it J Mol Graph Model 2021
[Effect of physicochemical properties on the pharmacokinetic parameters of the new representative of benzothiazinones antituberculosis drug macozinonе]. doi:10.26442/00403660.2020.12.200482 Ter Arkh 2020
Chemical Tools for Illumination of Tuberculosis Biology, Virulence Mechanisms, and Diagnosis. doi:10.1021/acs.jmedchem.0c01337 J Med Chem 2020
Biological Profiling Enables Rapid Mechanistic Classification of Phenotypic Screening Hits and Identification of KatG Activation-Dependent Pyridine Carboxamide Prodrugs With Activity Against Mycobacterium tuberculosis. doi:10.3389/fcimb.2020.582416 Front Cell Infect Microbiol 2020
A Simple Work-Up-free, Solvent-free Approach to Novel Amino Acid Linked 1,4-Disubstituted 1,2,3-Triazoles as Potent Antituberculosis Agents. doi:10.1021/acsomega.0c03862 ACS Omega 2020
In vitro and in vivo antimicrobial activities of a novel piperazine-containing benzothiazinones candidate TZY-5-84 against Mycobacterium tuberculosis. doi:10.1016/j.biopha.2020.110777 Biomed Pharmacother 2020
Structure based pharmacophore modelling approach for the design of azaindole derivatives as DprE1 inhibitors for tuberculosis. doi:10.1016/j.jmgm.2020.107718 names it J Mol Graph Model 2020
Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents. doi:10.1016/j.ejmech.2020.112773 names it Eur J Med Chem 2020
Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against M. tuberculosis Enzyme Targets. doi:10.2174/1568026620666200903163921 Curr Top Med Chem 2020
[The main results of clinical trials of the efficacy, safety and pharmacokinetics of the perspective anti-tuberculosis drug makozinone (PBTZ169)]. doi:10.26442/00403660.2020.03.000621 Ter Arkh 2020
6-Nitro-1-benzylquinolones exhibiting specific antitubercular activity. doi:10.1111/cbdd.13747 Chem Biol Drug Des 2020
Pyrazole-coumarin and pyrazole-quinoline chalcones as potential antitubercular agents. doi:10.1002/ardp.202000077 Arch Pharm (Weinheim) 2020
Optimization of Hydantoins as Potent Antimycobacterial Decaprenylphosphoryl-β-d-Ribose Oxidase (DprE1) Inhibitors. doi:10.1021/acs.jmedchem.0c00107 names it J Med Chem 2020
Identification of 2-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)amino)-N-phenylpropanamides as a novel class of potent DprE1 inhibitors. doi:10.1016/j.bmcl.2020.127192 names it Bioorg Med Chem Lett 2020
OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor. doi:10.1128/AAC.02020-19 names it Antimicrob Agents Chemother 2020
Computer-aided Drug Design Investigations for Benzothiazinone Derivatives Against Tuberculosis. doi:10.2174/1386207323666200117102316 Comb Chem High Throughput Screen 2020
Mycobacterium tuberculosis Decaprenylphosphoryl-β-d-ribose Oxidase Inhibitors: Expeditious Reconstruction of Suboptimal Hits into a Series with Potent in Vivo Activity. doi:10.1021/acs.jmedchem.9b01561 J Med Chem 2020
Target Discovery for New Antitubercular Drugs Using a Large Dataset of Growth Inhibitors from PubChem. doi:10.2174/1871526519666181205163810 Infect Disord Drug Targets 2020
Scaffold Morphing To Identify Novel DprE1 Inhibitors with Antimycobacterial Activity. doi:10.1021/acsmedchemlett.9b00343 names it ACS Med Chem Lett 2019
Deuteration of BTZ043 Extends the Lifetime of Meisenheimer Intermediates to the Antituberculosis Nitroso Oxidation State. doi:10.1021/acsmedchemlett.9b00308 ACS Med Chem Lett 2019
Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β-d-ribofuranose 2'-Oxidase. doi:10.1021/acs.jmedchem.9b00912 J Med Chem 2019
Spirocyclic and Bicyclic 8-Nitrobenzothiazinones for Tuberculosis with Improved Physicochemical and Pharmacokinetic Properties. doi:10.1021/acsmedchemlett.8b00634 ACS Med Chem Lett 2019
Mycobacterial tuberculosis Enzyme Targets and their Inhibitors. doi:10.2174/1568026619666190219105722 Curr Top Med Chem 2019
Identification of a pyrimidinetrione derivative as the potent DprE1 inhibitor by structure-based virtual ligand screening. doi:10.1016/j.bioorg.2018.12.018 names it Bioorg Chem 2019
Novel Benzylidenehydrazide-1,2,3-Triazole Conjugates as Antitubercular Agents: Synthesis and Molecular Docking. doi:10.2174/1389557518666180718124858 Mini Rev Med Chem 2019
Synthesis, biological evaluation and molecular docking studies of 6-(4-nitrophenoxy)-1H-imidazo[4,5-b]pyridine derivatives as novel antitubercular agents: future DprE1 inhibitors. doi:10.1186/s13065-018-0515-1 names it Chem Cent J 2018
Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors. doi:10.1021/acs.jmedchem.8b01356 names it J Med Chem 2018
Discovery and Structure-Activity-Relationship Study of N-Alkyl-5-hydroxypyrimidinone Carboxamides as Novel Antitubercular Agents Targeting Decaprenylphosphoryl-β-d-ribose 2'-Oxidase. doi:10.1021/acs.jmedchem.8b00883 J Med Chem 2018
Identification of novel benzothiopyranone compounds against Mycobacterium tuberculosis through scaffold morphing from benzothiazinones. doi:10.1016/j.ejmech.2018.09.042 Eur J Med Chem 2018
Fluorescent Benzothiazinone Analogues Efficiently and Selectively Label Dpre1 in Mycobacteria and Actinobacteria. doi:10.1021/acschembio.8b00790 names it ACS Chem Biol 2018
Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1. doi:10.1038/s41598-018-31316-6 names it Sci Rep 2018
In Vitro Activity of PBTZ169 against Multiple Mycobacterium Species. doi:10.1128/AAC.01314-18 Antimicrob Agents Chemother 2018
Rapid and specific labeling of single live Mycobacterium tuberculosis with a dual-targeting fluorogenic probe. doi:10.1126/scitranslmed.aar4470 Sci Transl Med 2018
Triazole-diindolylmethane conjugates as new antitubercular agents: synthesis, bioevaluation, and molecular docking. doi:10.1039/c8md00055g Medchemcomm 2018
Structure-Based Drug Design and Characterization of Sulfonyl-Piperazine Benzothiazinone Inhibitors of DprE1 from Mycobacterium tuberculosis. doi:10.1128/AAC.00681-18 names it Antimicrob Agents Chemother 2018
Decaprenyl-phosphoryl-ribose 2'-epimerase (DprE1): challenging target for antitubercular drug discovery. doi:10.1186/s13065-018-0441-2 names it Chem Cent J 2018
Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis. doi:10.1021/acs.jmedchem.8b00281 names it J Med Chem 2018
Metabolism of SKLB-TB1001, a Potent Antituberculosis Agent, in Animals. doi:10.1128/AAC.02375-17 Antimicrob Agents Chemother 2018
Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles. doi:10.1039/c8ra00720a RSC Adv 2018
Drug discovery in tuberculosis. New drug targets and antimycobacterial agents. doi:10.1016/j.ejmech.2018.03.020 Eur J Med Chem 2018
Virtual Screening of Small Molecular Inhibitors against DprE1. doi:10.3390/molecules23030524 names it Molecules 2018
Current Affairs, Future Perspectives of Tuberculosis and Antitubercular Agents. doi:10.1016/j.ijtb.2017.08.011 Indian J Tuberc 2018
The frequently occurring components of essential oils beta elemene and R-limonene alter expression of dprE1 and clgR genes of Mycobacterium tuberculosis H37Ra. doi:10.1016/j.fct.2017.12.052 names it Food Chem Toxicol 2018
Promoter mutagenesis for fine-tuning expression of essential genes in Mycobacterium tuberculosis. doi:10.1111/1751-7915.12875 Microb Biotechnol 2018
Identification of Potential Antituberculosis Drugs Through Docking and Virtual Screening. doi:10.1007/s12539-016-0175-6 Interdiscip Sci 2018
Design, Synthesis, Antimycobacterial Evaluation, and In Silico Studies of 3-(Phenylcarbamoyl)-pyrazine-2-carboxylic Acids. doi:10.3390/molecules22091491 Molecules 2017
Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes. doi:10.1002/anie.201707324 names it Angew Chem Int Ed Engl 2017
Structural and inhibition analysis of novel sulfur-rich 2-mercaptobenzothiazole and 1,2,3-triazole ligands against Mycobacterium tuberculosis DprE1 enzyme. doi:10.1007/s00894-017-3403-z names it J Mol Model 2017
Synthesis and biological evaluation of novel 1,2,3-triazole derivatives as anti-tubercular agents. doi:10.1016/j.bmcl.2017.07.008 Bioorg Med Chem Lett 2017
The VAO/PCMH flavoprotein family. doi:10.1016/j.abb.2017.06.022 Arch Biochem Biophys 2017
Learning from the past for TB drug discovery in the future. doi:10.1016/j.drudis.2016.09.025 Drug Discov Today 2017
Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors. doi:10.1016/j.drudis.2016.09.014 names it Drug Discov Today 2017
New and Old Hot Drug Targets in Tuberculosis. doi:10.2174/1389557516666160831164925 Curr Med Chem 2016
Synthesis and Antitubercular Activity of New Benzo[b]thiophenes. doi:10.1021/acsmedchemlett.6b00077 ACS Med Chem Lett 2016
Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis. doi:10.1128/AAC.01523-16 names it Antimicrob Agents Chemother 2016
N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis. doi:10.1073/pnas.1606590113 Proc Natl Acad Sci U S A 2016
Benzothiazinethione is a potent preclinical candidate for the treatment of drug-resistant tuberculosis. doi:10.1038/srep29717 Sci Rep 2016
Sulphur-Containing Heterocycles as Antimycobacterial Agents: Recent Advances in Thiophene and Thiadiazole Derivatives. doi:10.2174/1568026616666160506131118 Curr Top Med Chem 2016
Synthesis and docking studies of pyrazine-thiazolidinone hybrid scaffold targeting dormant tuberculosis. doi:10.1016/j.bmcl.2016.03.055 Bioorg Med Chem Lett 2016
Design, Syntheses, and Anti-TB Activity of 1,3-Benzothiazinone Azide and Click Chemistry Products Inspired by BTZ043. doi:10.1021/acsmedchemlett.5b00424 ACS Med Chem Lett 2016
Nitroarenes as Antitubercular Agents: Stereoelectronic Modulation to Mitigate Mutagenicity. doi:10.1002/cmdc.201500462 ChemMedChem 2016
Synthesis and bioactivity of novel triazole incorporated benzothiazinone derivatives as antitubercular and antioxidant agent. doi:10.1016/j.bmcl.2015.11.071 Bioorg Med Chem Lett 2016
Whole Cell Target Engagement Identifies Novel Inhibitors of Mycobacterium tuberculosis Decaprenylphosphoryl-β-d-ribose Oxidase. doi:10.1021/acsinfecdis.5b00065 ACS Infect Dis 2015
Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidase. doi:10.1016/j.bmc.2015.11.017 Bioorg Med Chem 2015
GtrA Protein Rv3789 Is Required for Arabinosylation of Arabinogalactan in Mycobacterium tuberculosis. doi:10.1128/JB.00628-15 J Bacteriol 2015
Design and synthesis of 11α-substituted bile acid derivatives as potential anti-tuberculosis agents. doi:10.1016/j.bmcl.2015.08.006 Bioorg Med Chem Lett 2015
The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis. doi:10.1128/AAC.00778-15 names it Antimicrob Agents Chemother 2015
Decaprenylphosphoryl-β-d-ribose 2'-Epimerase 1 (DprE1): A Novel Therapeutic Target for the Treatment of Tuberculosis. doi:10.1021/acsmedchemlett.5b00080 names it ACS Med Chem Lett 2015
DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization. doi:10.1021/acschembio.5b00237 names it ACS Chem Biol 2015
Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides. doi:10.1016/j.ejmech.2015.04.011 names it Eur J Med Chem 2015
Structure, dynamics, and interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 examined by molecular modeling, simulation, and electrostatic studies. doi:10.1371/journal.pone.0119771 names it PLoS One 2015
Synthesis and antitubercular evaluation of 4-carbonyl piperazine substituted 1,3-benzothiazin-4-one derivatives. doi:10.1016/j.bmcl.2015.02.061 Bioorg Med Chem Lett 2015
Syntheses and Antituberculosis Activity of 1,3-Benzothiazinone Sulfoxide and Sulfone Derived from BTZ043. doi:10.1021/ml5003458 ACS Med Chem Lett 2015
2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. doi:10.1021/cb5007163 names it ACS Chem Biol 2015
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosis. doi:10.1021/ml5001933 ACS Med Chem Lett 2014
Elucidation of a protein-protein interaction network involved in Corynebacterium glutamicum cell wall biosynthesis as determined by bacterial two-hybrid analysis. doi:10.1007/s10719-014-9549-3 Glycoconj J 2014
Trends in discovery of new drugs for tuberculosis therapy. doi:10.1038/ja.2014.109 J Antibiot (Tokyo) 2014
1,4-azaindole, a potential drug candidate for treatment of tuberculosis. doi:10.1128/AAC.03233-14 Antimicrob Agents Chemother 2014
Design and Syntheses of Anti-Tuberculosis Agents Inspired by BTZ043 Using a Scaffold Simplification Strategy. doi:10.1021/ml500039g ACS Med Chem Lett 2014
Lead optimization of 1,4-azaindoles as antimycobacterial agents. doi:10.1021/jm500571f J Med Chem 2014
4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity. doi:10.1021/jm5005978 names it J Med Chem 2014
Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. doi:10.1021/jm5002937 names it J Med Chem 2014
Sulfur rich 2-mercaptobenzothiazole and 1,2,3-triazole conjugates as novel antitubercular agents. doi:10.1016/j.ejmech.2014.02.017 Eur J Med Chem 2014
Assessing the essentiality of the decaprenyl-phospho-d-arabinofuranose pathway in Mycobacterium tuberculosis using conditional mutants. doi:10.1111/mmi.12546 Mol Microbiol 2014
Towards a new combination therapy for tuberculosis with next generation benzothiazinones. doi:10.1002/emmm.201303575 EMBO Mol Med 2014
Benzothiazinones mediate killing of Corynebacterineae by blocking decaprenyl phosphate recycling involved in cell wall biosynthesis. doi:10.1074/jbc.M113.522623 J Biol Chem 2014
Prokaryotic Expression, Identification and Bioinformatics Analysis of the Mycobacterium tuberculosis Rv3807c Gene Encoding the Putative Enzyme Committed to Decaprenylphosphoryl-d-arabinose Synthesis. doi:10.1007/s12088-013-0418-8 Indian J Microbiol 2014
DprE1--from the discovery to the promising tuberculosis drug target. doi:10.2174/138161282027140630122724 names it Curr Pharm Des 2014
Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship. doi:10.2174/1381612819666131118203915 Curr Pharm Des 2014
Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. doi:10.1021/jm401382v names it J Med Chem 2013
A large scale virtual screen of DprE1. doi:10.1016/j.compbiolchem.2013.08.006 names it Comput Biol Chem 2013
The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis. doi:10.1007/s00253-013-5218-x names it Appl Microbiol Biotechnol 2013
DprE1, a new taxonomic marker in mycobacteria. doi:10.1111/1574-6968.12246 names it FEMS Microbiol Lett 2013
Synthesis and structure-activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents. doi:10.1016/j.bmcl.2013.06.069 Bioorg Med Chem Lett 2013
Identification of a small molecule with activity against drug-resistant and persistent tuberculosis. doi:10.1073/pnas.1309171110 Proc Natl Acad Sci U S A 2013
Thiolates chemically induce redox activation of BTZ043 and related potent nitroaromatic anti-tuberculosis agents. doi:10.1021/ja311058q J Am Chem Soc 2013
Crystal structure of decaprenylphosphoryl-β- D-ribose 2'-epimerase from Mycobacterium smegmatis. doi:10.1002/prot.24220 Proteins 2013
A small multidrug resistance-like transporter involved in the arabinosylation of arabinogalactan and lipoarabinomannan in mycobacteria. doi:10.1074/jbc.M112.400986 J Biol Chem 2012
Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis. doi:10.1126/scitranslmed.3004395 Sci Transl Med 2012
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. doi:10.1128/AAC.01476-12 Antimicrob Agents Chemother 2012
Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. doi:10.1073/pnas.1205735109 names it Proc Natl Acad Sci U S A 2012
Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. doi:10.1021/cb300151m ACS Chem Biol 2012
Antituberculars which target decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1: state of art. doi:10.1007/s00253-012-4013-4 names it Appl Microbiol Biotechnol 2012
Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2'-oxidase DprE1. doi:10.1021/ja211042r names it J Am Chem Soc 2012
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. doi:10.1371/journal.pone.0026675 PLoS One 2011
New tuberculosis drugs on the horizon. doi:10.1016/j.mib.2011.07.022 Curr Opin Microbiol 2011
Pseudomonas aeruginosa D-arabinofuranose biosynthetic pathway and its role in type IV pilus assembly. doi:10.1074/jbc.M111.255794 J Biol Chem 2011
Identifying vulnerable pathways in Mycobacterium tuberculosis by using a knockdown approach. doi:10.1128/AEM.02880-10 Appl Environ Microbiol 2011
The effect of MSMEG_6402 gene disruption on the cell wall structure of Mycobacterium smegmatis. doi:10.1016/j.micpath.2011.04.005 Microb Pathog 2011
Decaprenylphosphoryl-β-D-ribose 2'-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis. doi:10.1371/journal.pone.0016869 PLoS One 2011
Leads for antitubercular compounds from kinase inhibitor library screens. doi:10.1016/j.tube.2010.09.001 Tuberculosis (Edinb) 2010
Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. doi:10.1021/ja106357w names it J Am Chem Soc 2010
Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target. doi:10.2174/092986710791959693 Curr Med Chem 2010
Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance. doi:10.1111/j.1365-2958.2010.07277.x Mol Microbiol 2010
Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. doi:10.1128/AAC.01676-09 Antimicrob Agents Chemother 2010
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. doi:10.1371/journal.ppat.1000645 PLoS Pathog 2009
Partial redundancy in the synthesis of the D-arabinose incorporated in the cell wall arabinan of Corynebacterineae. doi:10.1099/mic.0.2008/016378-0 Microbiology (Reading) 2008
Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy. doi:10.1111/j.1742-4658.2008.06395.x FEBS J 2008
Decaprenylphosphoryl arabinofuranose, the donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. doi:10.1128/JB.187.23.8020-8025.2005 J Bacteriol 2005

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature and adds context; it does not change the verdict or the function stated elsewhere in this fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole): H37Rv locus tag + GENE NAME + ortholog identifiers (Mb…, MMAR_…, MSMEG_…, ML…, MAB_…), under a mycobacterial context filter; hits verified against the abstract text. Species-context counts distinguish M. tuberculosis literature from literature on other mycobacteria. phase76/phase77, 2026-07-13.

CRISPRi vulnerability

Vulnerability index -9.42 (95% CI -10.44 to -8.36). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Legacy record & comparison (Mycobrowser)

Mycobrowser functionTogether with DPRE2|Rv3791, catalyzes epimerization of decaprenylphosphoryl ribose (DPR) to decaprenylphosphoryl arabinose (DPA) in arabinan synthesis
Mycobrowser EC 1.-.-.- · superseded EC numbering; the atlas uses the current class (1.1.98.3)

The legacy Mycobrowser record is shown for verification. Mycobrowser is no longer maintained; its EC numbers predate recent nomenclature revisions, so a class change usually reflects re-numbering, not a conflict.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb3819 · 100.0% identity
M. leprae ML0109c · 86.6% identity
M. marinum MMAR_5352 · 87.9% identity
M. smegmatis MSMEG_6382 · 84.4% identity
M. orygis RJtmp_003902 · 100.0% identity
M. abscessus MAB_0192c · 67.9% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt P9WJF1 SwissProt · reviewed · Evidence at protein level
UniProt nameDecaprenylphosphoryl-beta-D-ribose oxidase
EC (curated) EC 1.1.98.3
Curated functionComponent of the DprE1-DprE2 complex that catalyzes the 2-step epimerization of decaprenyl-phospho-ribose (DPR) to decaprenyl-phospho-arabinose (DPA), a key precursor that serves as the arabinose donor required for the synthesis of cell-wall arabinans. DprE1 catalyzes the first step of epimerization, namely FAD-dependent oxidation of the C2' hydroxyl of DPR to yield the keto intermediate decaprenyl-phospho-2'-keto-D-arabinose (DPX). The intermediate DPX is then transferred to DprE2 subunit of the epimerase complex, most probably through a 'substrate channel' at the interface of DprE1-DprE2 com.

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category C Energy production and conversion
Preferred namedprE1
eggNOG descriptionFAD linked oxidase
Orthologous groupCOG0277
EC number EC 1.1.98.3
KEGG orthology K16653
Gene Ontology (39) GO:0000271, GO:0005575, GO:0005623, GO:0005886, GO:0005975, GO:0005976, GO:0008150, GO:0008152, GO:0009058, GO:0009059, GO:0009987, GO:0010383 +27 more

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Conservation & selection (intra-MTBC, 142 601 strains, snapshot of 2026-09-29)

pN/pS 0.222 · quasi-invariant (5 sites), pN/pS underpowered
Polymorphic sites (≥ 0.1% of strains) 3 synonymous, 2 missense, 0 nonsense, 0 frameshift

pN/pS from segregating SNPs (singletons removed) normalised by possible sites. Low pN/pS = purifying selection (a strong signal that a "hypothetical" is a real, constrained gene). A high pN/pS is ambiguous: relaxed constraint or positive selection (drug resistance, antigenic variation) inflate it; e.g. rpoB/katG/pncA score high here for resistance, not loss of function. A clonal disruption (one allele over a clade) suggests lineage pseudogenisation; a convergent one (many independent alleles) is typical of resistance loss-of-function.

Outgroup conservation (beyond the MTBC) Actinomycetia

M. canettii dN/dS (deep-divergence selection) 0.333 (low power) · 4 consensus substitution(s)
low power (4 canettii-consensus substitution(s)); present in M. canettii but dN/dS not reliable
Limitation: dN/dS mixes fixed canettii-H37Rv divergence with intra-canettii polymorphism, and is not polarised (the per-gene repolarisation is not viable: 79 % of the consensus SPDI lie outside the polarised table).
Genus-wide presence (~53 non-MTBC Mycobacterium) present in 53/53 (100%) · mean identity 80.3% · 4/4 closest MTBAP relatives
conserved across the genus (present in 53/53 non-MTBC Mycobacterium genomes, incl. distant relatives) — an ancient core gene predating the genus radiation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 8/13 non-Mycobacterium reference genomes (down to Actinomycetia) · mean identity 65.3%
detected across the class Actinomycetia (beyond Corynebacteriales) but not outside the phylum — an Actinobacteria-level ancient gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis) essential

DeJesus 2017 callES · essential
What the call meansessential: insertions absent across the whole ORF
TA sites (Himar1) 28 in the ORF — 25 in the essential state, 0 growth-defect, 3 non-essential, 0 growth-advantage. Saturation 0.107, mean read count 65.3333333333. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
All 28 sites lie in this ORF alone (no overlapping CDS shares any), so the call is attributable to this gene.

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Chemical-genetic target & druggability (PROSPECT) hypomorph tool strain

This gene is part of the PROSPECT collection of TetON transcriptional-knockdown (hypomorph) strains of essential M. tuberculosis genes, built as a sensitised background for chemical-genetic mechanism-of-action deconvolution. Being in the panel means the gene is an essential / vulnerable target for which a validated knockdown tool strain exists.

Hypomorph strainRv3790-dprE1_TetOn18.1 (TetON promoter 18)
Baseline knockdown fitness4.467 median doublings (across 6 screen pool(s)) — fewer doublings = stronger growth defect on knockdown
Used in target deconvolutionyes (informs phenotypic-cluster / MOA assignment)

Panel membership reflects essentiality/vulnerability and the availability of a genetic tool, not a specific molecular function; it never changes the verdict here. Source: Bond AN et al., Nat Commun 2025;16:9673 (doi:10.1038/s41467-025-64662-x); PROSPECT chemical-genetic platform.

Proteomics (mass spectrometry) detected

MS detectiondetected in 12 of 16 independent MS datasets
Integrated abundance66.6 ppm · rank 1568/3519 (55.5th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox) no export signal, no TM helix

Predictionno signal peptide, no TM helix (DeepTMHMM class GLOB)
DeepTMHMM classGLOB

A verified absence of signals, which is not a compartment. No Sec/Tat signal peptide, no transmembrane helix and no lipobox were found on this sequence. The predictor reports topology and export signals; it does not measure where the protein ends up, so this page draws no cytoplasmic conclusion from it. In M. tuberculosis that reservation is not theoretical: the 12 Esx paralogues of this atlas — EsxA/ESAT-6 and EsxB/CFP-10 among them, the best-established secreted proteins of the species — carry this very call, because substrates of the type VII (ESX) secretion system leave no recognisable signal. « Secreted » and « no signal peptide » are true together here.

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length461 aa
Molecular weight50.2 kDa
Theoretical pI7.17
GRAVY-0.102 (hydrophilic)
Aliphatic index86.2
Aromaticity0.093
Instability index28.2 (stable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
FAD_binding_4PF01565.29 1.9e-2430–161 FAD binding domain
ALOPF04030.20 3.8e-07399–457 D-arabinono-1,4-lactone oxidase

3D structure (interactive — Mol*/pdbe-molstar)

Experimental structure 4p8n (PDBe), the strongest available structural evidence for this gene. Drag to rotate, scroll to zoom; hetero-groups (ligands, ions, waters hidden by default) shown as sticks.

Experimental structures (Protein Data Bank) 27 solved

PDBMethodResolutionCoverage
4p8n X-ray diffraction 1.79 Å 100%
4ncr X-ray diffraction 1.881 Å 100%
4p8c X-ray diffraction 1.95 Å 100%
4p8y X-ray diffraction 2.01 Å 100%
4p8l X-ray diffraction 2.02 Å 100%
4feh X-ray diffraction 2.035 Å 100%
6hfv X-ray diffraction 2.05 Å 100%
4p8m X-ray diffraction 2.09 Å 100%

Experimentally solved structures mapped from the UniProt accession via PDBe/SIFTS (27 total; up to 8 shown, ranked by sequence coverage then resolution). An experimental structure is direct proof of the folded product and the strongest structural evidence — superseding the predicted ESMFold/AlphaFold models below for any covered region.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 94.8

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
4p8t-assembly1_A 1.00 0.93 0.92 0.93 100% 99% / 100% 1.6e-89 sig 4p8t-assembly1_A Crystal structure of M. tuberculosis DprE1 in complex with the non-covalent inhibitor QN129
4p8m-assembly1_A 1.00 0.98 0.90 0.98 94% 98% / 100% 2.9e-85 sig 4p8m-assembly1_A Crystal structure of M. tuberculosis DprE1 in complex with the non-covalent inhibitor QN114
5oel-assembly1_A 1.00 0.94 0.92 0.94 98% 99% / 100% 1.4e-88 sig 5oel-assembly1_A Mycobacterium tuberculosis DprE1 mutant Y314C in complex with TCA1
6hfv-assembly1_A 1.00 0.96 0.89 0.96 94% 99% / 100% 4.3e-86 sig 6hfv-assembly1_A Mycobacterium tuberculosis DprE1 in complex with CMP2
4p8n-assembly1_A 1.00 0.93 0.92 0.93 99% 99% / 100% 2.2e-88 sig 4p8n-assembly1_A Crystal structure of M. tuberculosis DprE1 in complex with the non-covalent inhibitor QN118

Foldseek search of the AlphaFold DB model (mean pLDDT 94.8, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Genomic context (neighbours & predicted operon) operon of 5

Upstream (5' on genome)Rv3789 (+ strand, 39 bp gap)
Downstream (3' on genome)dprE2 (+ strand, 0 bp gap)
Predicted operon Rv3789 · dprE1 · dprE2 · aftA · embC

Neighbours from the H37Rv annotation (+ strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) operon of 3: dprE1 · dprE2 · aftA — disagrees with the distance heuristic above
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT3898) exponential phase: operon of 4, Rv3790 · Rv3791 · Rv3792 · Rv3793 (coverage 45.14)
not expressed (stationary phase) — disagrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: dprE2 (decaprenylphosphoryl-D-2-keto erythropentose reductase), high confidence (score 988, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence). The pair is recorded in a curated database (pathway or complex membership) for M. tuberculosis genes themselves (score ≥ 200): a curated association, not a measurement in this organism.

Showing the 15 strongest of this gene's 47 partners at medium confidence (12 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. None of the 47 partners rests on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv3791 dprE2 curated decaprenylphosphoryl-D-2-keto erythropentose reductase 999 988 ctx neighborhood:881 cooccurence:774 database:500 textmining:947
Rv3789 GtrA family protein 965 958 ctx neighborhood:823 cooccurence:762
Rv3793 embC arabinosyltransferase C 972 941 ctx neighborhood:881 cooccurence:486 textmining:542
Rv3792 aftA arabinofuranosyltransferase 933 904 ctx neighborhood:881
Rv3806c ubiA curated decaprenyl-phosphate phosphoribosyltransferase 965 899 ctx cooccurence:774 database:552 textmining:675
Rv3794 embA arabinosyltransferase A 872 791 ctx neighborhood:601 cooccurence:455 textmining:413
Rv3795 embB arabinosyltransferase B 852 788 ctx neighborhood:580 cooccurence:493
Rv2073c oxidoreductase 787 786 ctx cooccurence:774
Rv3788 hypothetical protein 744 745 ctx neighborhood:732
Rv3807c curated decaprenylphosphoryl-5-phosphoribose phosphatase 879 650 database:500 textmining:670
Rv2482c plsB2 curated glycerol-3-phosphate acyltransferase 644 603 database:549
Rv1551 plsB1 curated acyltransferase PlsB 619 602 database:549
Rv1501 curated hypothetical protein 600 586 database:463
Rv2036 hypothetical protein 577 578 ctx neighborhood:500
Rv1310 atpD curated ATP synthase subunit beta 573 558 database:538

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Legacy H37Rv annotation: decaprenylphosphoryl-beta-D-ribose oxidase
  • MTBC0 PGAP product: decaprenylphospho-beta-D-ribofuranose 2-dehydrogenase DprE1
  • Pfam (hmmscan --cut_ga): FAD_binding_4 PF01565.29 (E=2e-24), ALO PF04030.20 (E=4e-07)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_218307.1)
  • Domains: Pfam-A via hmmscan --cut_ga — FAD_binding_4 (PF01565.29), ALO (PF04030.20)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG0277
  • Curated reference: UniProt P9WJF1 (SwissProt, reviewed; Evidence at protein level)
  • Intra-MTBC selection: pN/pS and disruption from SPDI variants of 142 601 MTBC strains (this work, local collection vs H37Rv NC_000962.3)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 94.8)
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 47 functional partner(s); context anchor dprE2
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Experimental structures: PDBe/SIFTS UniProt→PDB mapping (Dana et al. 2019, doi:10.1093/nar/gky1114)
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>mtbc0_004018|Rv3790|dprE1
MLSVGATTTATRLTGWGRTAPSVANVLRTPDAEMIVKAVARVAESGGGRGAIARGLGRSYGDNAQNGGGLVIDMTPLNTIHSIDADTKLVDIDAGVNLDQLMKAALPFGLWVPVLPGTRQVTVGGAIACDIHGKNHHSAGSFGNHVRSMDLLTADGEIRHLTPTGEDAELFWATVGGNGLTGIIMRATIEMTPTSTAYFIADGDVTASLDETIALHSDGSEARYTYSSAWFDAISAPPKLGRAAVSRGRLATVEQLPAKLRSEPLKFDAPQLLTLPDVFPNGLANKYTFGPIGELWYRKSGTYRGKVQNLTQFYHPLDMFGEWNRAYGPAGFLQYQFVIPTEAVDEFKKIIGVIQASGHYSFLNVFKLFGPRNQAPLSFPIPGWNICVDFPIKDGLGKFVSELDRRVLEFGGRLYTAKDSRTTAETFHAMYPRVDEWISVRRKVDPLRVFASDMARRLELL